Lineage Cell Therapeutics Inc [LCTX] stock is trading at $0.51, up 5.25%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The LCTX shares have gain 11.59% over the last week, with a monthly amount glided 18.92%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Lineage Cell Therapeutics Inc [AMEX: LCTX] stock has seen the most recent analyst activity on August 20, 2024, when Craig Hallum initiated its Buy rating and assigned the stock a price target of $4. Previously, Robert W. Baird started tracking the stock with Outperform rating on November 02, 2022, and set its price target to $5. On June 14, 2022, B. Riley Securities initiated with a Buy rating and assigned a price target of $4 on the stock. Noble Capital Markets started tracking the stock assigning a Outperform rating and suggested a price target of $8 on August 19, 2021. Cantor Fitzgerald initiated its recommendation with a Overweight and recommended $6 as its price target on March 31, 2021.
Lineage Cell Therapeutics Inc [LCTX] stock has fluctuated between $0.37 and $1.15 over the past year. Lineage Cell Therapeutics Inc [AMEX: LCTX] shares were valued at $0.51 at the most recent close of the market.
Analyzing the LCTX fundamentals
Lineage Cell Therapeutics Inc [AMEX:LCTX] reported sales of 9.56M for the trailing twelve months, which represents a growth of 4.02%. Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -2.23%, Pretax Profit Margin comes in at -1.69%, and Net Profit Margin reading is -1.7%. To continue investigating profitability, this company’s Return on Assets is posted at -0.15, Equity is -0.22 and Total Capital is -0.22. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Lineage Cell Therapeutics Inc’s Current Ratio is 3.82. Also, the Quick Ratio is 3.82, while the Cash Ratio stands at 3.66. Considering the valuation of this stock, the price to sales ratio is 12.21, the price to book ratio is 1.48.
Transactions by insiders
Recent insider trading involved BROADWOOD PARTNERS, L.P., Director, that happened on Jan 27 ’25 when 7.89 million shares were purchased. Chief Financial Officer, Howe Jill Ann completed a deal on Nov 26 ’24 to buy 15000.0 shares. Meanwhile, General Counsel Samuel George A. III bought 15000.0 shares on Nov 26 ’24.
